Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12000726 | 0.92 | — | — | |
| SCHEMBL6057217 | 0.92 | ALOX15 (0.38) | SIGMAR1TP53SMN1; SMN2 | |
| SCHEMBL20438382 | 0.92 | ALOX15 (0.38) | SIGMAR1TP53SMN1; SMN2 | |
| SCHEMBL17806050 | 0.91 | CHKA (0.43) | SIGMAR1ALDH1A1 | |
| SCHEMBL24513247 | 0.87 | KDM4E (0.38) | PAOXSMN1; SMN2GAA | |
| SCHEMBL25730522 | 0.87 | KDM4E (0.40) | PAOXMC4R | |
| SCHEMBL438183 | 0.85 | PAOX (0.44) | PAOXSIGMAR1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL438495 | 0.85 | SIGMAR1 (0.33) | SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL105381 | 0.83 | PAOX (0.47) | PAOXSIGMAR1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL25123284 | 0.82 | GBA1 (0.43) | TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239804-A1 | FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 | BAYER AKTIENGESELLSCHAFT (DE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239804-A1 | FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 | BAYER AKTIENGESELLSCHAFT (DE) | 2024-07-18 | — | — | US | disclosed |
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-12024484-B2 | Lipid formulations for gene editing | VERVE THERAPEUTICS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024092011-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023244806-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11834448-B2 | 2-amino-quinoline derivatives | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-12-05 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070197546-A1 | QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM SPA, ITALY | 2007-08-23 | — | — | US | disclosed |
| US-20070197546-A1 | QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM SPA, ITALY | 2007-08-23 | — | — | US | disclosed |
| US-7235563-B2 | Spirocyclic compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070142268-A1 | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif | OSCIENT PHARMACEUTICALS CORPORATION (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| WO-2007038669-A2 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2007-04-05 | — | — | WO | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20070015771-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024484-B2 | Lipid formulations for gene editing | LIPA, LIPC, ABHD16A | PAOX 468/4885MC4R 3289/4885SIGMAR1 2373/4885 |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | PAOX 3319/4885MC4R 2255/4885SIGMAR1 3266/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | PAOX 2674/4885MC4R 335/4885SIGMAR1 3649/4885 |
| US-11834448-B2 | 2-amino-quinoline derivatives | TLR7, TLR8, TLR1 | PAOX 1456/4885MC4R 596/4885SIGMAR1 1470/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | PAOX 2057/4885MC4R 4234/4885SIGMAR1 4116/4885 |
| US-20070142268-A1 | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif | AADAC, MRPL21, HDAC6 | PAOX 2062/4885MC4R 2433/4885SIGMAR1 1670/4885 |
| US-20070197546-A1 | QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | KCNH2, KCNH3, KCNJ2 | PAOX 4389/4885MC4R 1623/4885SIGMAR1 350/4885 |
| US-20070015771-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | PAOX 1898/4885MC4R 932/4885SIGMAR1 2216/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | PAOX 1271/4885MC4R 795/4885SIGMAR1 1412/4885 |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | VDR, ESRRB, NR5A1 | PAOX 537/4885MC4R 461/4885SIGMAR1 1488/4885 |
| US-20240239804-A1 | FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 | GPR84, GPR88, FFAR1 | PAOX 266/4885MC4R 103/4885SIGMAR1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.